Tap any paragraph to write a margin note. Your notes collect in the Desk below the text and file under cases with @. The side-by-side margin rail opens on a larger screen.

Code · CFR · Title 21 — Food and Drugs · Part 862 — Clinical Chemistry and Clinical Toxicology Devices · § 862.1092

§ 862.1092. Anti-mullerian hormone test system.

255 words·~1 min read·/us/cfr/t21/s§ 862.1092·

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

(a)Identification. An anti-mullerian hormone test system is an in vitro diagnostic device intended to measure anti-mullerian hormone in human serum and plasma. An anti-mullerian hormone test system is intended to be used for assessing ovarian reserve in women.
(b)Classification. Class II (special controls). The special controls for this device are:
(1)Design verification and validation must include:
(i)An adequate traceability plan to minimize the risk of drift in anti-mullerian hormone test system results over time.
(ii)Detailed documentation of a prospective clinical study to demonstrate clinical performance or, if appropriate, results from an equivalent sample set. This detailed documentation must include the following information:
(A)Results must demonstrate adequate clinical performance relative to a well-accepted comparator.
(B)Clinical sample results must demonstrate consistency of device output throughout the device measuring range that is appropriate for the intended use population.
(C)Clinical study documentation must include the original study protocol (including predefined statistical analysis plan), study report documenting support for the proposed indications for use(s), and results of all statistical analyses.
(iii)Reference intervals generated by testing an adequate number of samples from apparently healthy normal individuals in the intended use population.
(2)The labeling required under § 809.10(b) of this chapter must include a warning statement that the device is intended to be used for assessing the ovarian reserve in conjunction with other clinical and laboratory findings before starting any fertility therapy, and that the device should be used in conjunction with the antral follicle count. [90 FR 22850, May 30, 2025]
Connections5 cite this
Cited by 5 sections · top 1
Citation graph
cites case law
§ 862.1092
Anti-mullerian hormone test system.
Fed. Reg.×5
Cites 0Cited by 5 across 1 source
★   the supreme law of the land   ★
Don't Tread on Me
E Pluribus Unum — out of many, one

"If you don't know your rights, you don't have any."

Marginalia · a citizen's law index
A research desk, not legal advice. Always read the cited source before relying on a summary.
Questions or an issue? support@self-law.org
disclaimerMarginalia is a research index, not a law firm. Nothing on this site is legal, tax, or financial advice and no attorney–client relationship is formed by using it. Statutes, regulations, and case law change; summaries, search results, AI output, and member posts may be incomplete, out of date, or wrong. Any interpretation drawn from material on this site should be validated by a licensed attorney in your jurisdiction before you act on it.